UNSPSC 51412103: Bendazol hydrochloride

This classification denotes a vasodilating agent C14H12N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ME751TL810, chemically known as 1h-benzimidazole, 2-(phenylmethyl)-, hydrochloride (1:1), but more generally known as bendazol hydrochloride, which bears US NIH Compound Identifier 164798. European Medicines Agency schedules Bendazol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32247.

Most nations, for tariff and trade purposes, schedule bendazol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BENDAZOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CC2[NH]C3CCCCC3N2.CL.

UNSPSC 51412103 Bendazol hydrochloride is a Commodity code representing pharmaceutical products purchased by state and local governments for emergency medical services, institutional healthcare, and pharmacy benefit programs. State and local buyers under this code procure specific pharmaceutical line items for fire rescue operations, hospital systems, and state health agencies, typically requiring compliance with FDA manufacturing standards, chain-of-custody documentation, expiration-date warranties, and safety data sheets. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances serving multiple jurisdictions. The City of Tampa's fire rescue department and the Texas Health and Human Services Commission represent the kinds of institutional and state-level buyers active under this code.

Recent activity shows geographic concentration in Texas and Florida, with broader multistate reach through cooperative purchasing vehicles. The City of Tampa Fire Rescue issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem with a response deadline of April 8, 2026 and an estimated contract value of $40,000, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission released RFI HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on direct contracting and value-based pricing models outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. Cooperative purchasing vehicles and multistate alliances appear to be the dominant procurement mechanism for volume pharmaceutical supply, while individual municipality and state agency solicitations address emergency-services and specialized-program needs.